Liraglutide (GLP-1 RA) significantly reduced the incidence of primary endpoint: CV death, nonfatal MI and nonfatal stroke death and overall mortality. There was a lower incidence of nephropathy and a non-significantly higher incidence of retinopathy in the liraglutide group. This evidence concerns the gene GLP1R and kidney disorder.